Christine Cassiano

[Christine Cassiano @TheOriginalC2]

@mickakers I'm not a @Raiders fan but I will say Mr. Davis was nice to every single person who came by and asked for a photo with him all night long. I applaud him for his grace (and for supporting the @GoldenKnights )! Next year VGK! Go Knights Go!

[BiotechTV @BiotechTV]

𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐂𝐡𝐚𝐧𝐠𝐞: @AllogeneTx is announcing a leadership change this afternoon. Current CEO David Chang is passing the baton to Zach Roberts. Both will join BiotechTV from #ASCO26 on Sunday. $ALLO

[Allogene Therapeutics @AllogeneTx]

Yesterday, we hosted our 8th annual Patient Day - a meaningful moment to reflect on the patients at the heart of our mission. Thank you to the entire Allogene team for your dedication to advancing #CART products. #allogeneic #celltherapy $ALLO

Learn More: https://t.co/3DEWU4rlzL

[Christine Cassiano @TheOriginalC2]

I’m incredibly proud of the work we’re doing at Allogene. Biotech drug development is challenging, but every bit of effort is worth it. I truly believe we’re on a path to change the trajectory of CAR T adoption and make this therapy accessible to more patients.

[Allogene Therapeutics @AllogeneTx]

LBCL patients face the fear of relapse after treatment ends. Our ALPHA3 trial is working to change that by testing a therapy aimed at preventing cancer from returning. Dr. Zachary Roberts joined @katiecouric to discuss the science behind this new approach.

Watch the full episode: https://t.co/KHwcjO2RLm

[Allogene Therapeutics @AllogeneTx]

ICYMI: @katiecouric highlighted the ALPHA3 trial evaluating an investigational allogeneic #CART therapy to help prevent relapse in high-risk #LBCL patients - advancing innovation in cancer care. $ALLO

Learn More: https://t.co/KCjqdb75X7

[Christine Cassiano @TheOriginalC2]

RT @AllogeneTx: Insights from our CEO David Chang on why today's acquisition of @capstantx by @abbvie signals a bright future ahead for cel…

[Allogene Therapeutics @AllogeneTx]

What if you could predict and prevent relapse in #DLBCL? Don’t miss this Satellite Symposium at #ICML2025, where experts will discuss potentially advancing beyond "watch and wait" with investigational MRD testing and allogeneic #CART. #Immunotherapy $ALLO

Register Here: https://t.co/WwOZmrKHmx

[Christine Cassiano @TheOriginalC2]

@tompowles1 @OncHahn - Nice meeting you at the bar in Joe's during AUA. This data you reposted is from @AllogeneTx (my company). I told you we'd cross paths again! It's a small world. This data is quite meaningful for advanced RCC patients; excited to share CAR T potential in ST at ASCO.

[BiotechTV @BiotechTV]

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: @AllogeneTx presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate. #ASCO25 $ALLO

Full video: https://t.co/ZdD8cTqn3W

[Allogene Therapeutics @AllogeneTx]

Exciting news! Allogene's next-gen "off-the-shelf" $CART product candidate, ALLO-329, received three FTDs for treating lupus, myositis and scleroderma. This is a major step toward transforming the treatment landscape and offering hope to patients. #celltherapy #innovation $ALLO Learn More: https://t.co/dTeplEGS1O

[Allogene Therapeutics @AllogeneTx]

Full Ph1 ALPHA/ALPHA2 cema-cel data in @JCO_ASCO, demonstrating long-term durability of a 1x Tx in r/r #LBCL patients with our investigational allogeneic #CART and 100% CR in patients with low disease burden – the focus of our ALPHA3 trial in 1L. $ALLO @DrFredLocke

Learn more about cema-cel: https://t.co/ciXShVQa1X

[Christine Cassiano @TheOriginalC2]

Such a sad time for all of us who were blessed to know David Bonderman.

[Dr. Arie Belldegrun @Arie_Belldegrun]

David Bonderman: my business partner, my mentor, my friend.
https://t.co/bSxyQBv3Yd

[Jason Westin, MD FACP FASCO @Lymphoma_Doc]

Important poster: ALPHA3, the first clinical trial enrolling patients with LBCL who have complete response by PET/CT after 1L therapy but have +ctDNA. Trial in Progress poster tonight at #ASH24 #lymsm

[Christine Cassiano @TheOriginalC2]

@UroGenPharma @lizforacure @Forbes @mcgrathmag Amazing leader!

[Allogene Therapeutics @AllogeneTx]

Last week, our One Allogene team joined @LLSusa's #LighttheNight walk in support of life-saving blood cancer research. Thank you to our amazing employees who came and showed their support! $ALLO

[STAT @statnews]

“How we scale and bring the promise of cell therapy to more patients is really, really critical.” https://t.co/Xy9FJuKLCK

[Christine Cassiano @TheOriginalC2]

@BiotechTVHQ Congratulations! Big news and so excited for you.

[Christine Cassiano @TheOriginalC2]

Apologies to anyone who received bizarre bitcoin tweets from my handle over the last few months. It was hijacked and took forever to get it back. Please - I'd never have a cat as my profile pic. Just saying.